Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Research Evaluating an Investigational Medication for Erectile Dysfunction - General ED (REVIVE-G)
This study is currently recruiting participants.
Verified by VIVUS, Inc., December 2008
Sponsors and Collaborators: VIVUS, Inc.
Quintiles
Information provided by: VIVUS, Inc.
ClinicalTrials.gov Identifier: NCT00790751
  Purpose

This study is being conducted to compare the safety and efficacy of 3 doses of avanafil to placebo in men with mild to severe erectile dysfunction.


Condition Intervention Phase
Erectile Dysfunction
Drug: placebo
Drug: avanafil
Phase III

MedlinePlus related topics: Erectile Dysfunction
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EVALUATION OF THE SAFETY AND EFFICACY OF AVANAFIL (TA-1790) IN SUBJECTS WITH GENERALIZED ERECTILE DYSFUNCTION

Further study details as provided by VIVUS, Inc.:

Primary Outcome Measures:
  • The change in percent of sexual attempts in which subjects are able to maintain an erection of sufficient duration to have successful intercourse. [ Time Frame: Between the run-in period and the 12-week treatment period ] [ Designated as safety issue: No ]
  • The change in percent of sexual attempts in which subjects are able to insert the penis into the partner's vagina. [ Time Frame: Between the run-in period and the 12-week treatment period ] [ Designated as safety issue: No ]
  • The change in score on the erectile function (EF) domain of the IIEF questionnaire. [ Time Frame: From baseline (visit 2) to end of treatment. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • The change in response to individual questions and for other domains (orgasmic function, sexual desire, intercourse satisfaction, overall satisfaction) from the IIEF [ Time Frame: Between screening and weeks 4, 8, and 12 ] [ Designated as safety issue: No ]
  • Responses to secondary subject diary questions [ Time Frame: Between the run-in period and week 12 ] [ Designated as safety issue: No ]
  • The response to the Global Assessment Question on treatment effect and the Future Use Question. [ Time Frame: Week 12 ] [ Designated as safety issue: No ]

Estimated Enrollment: 600
Study Start Date: November 2008
Estimated Study Completion Date: August 2009
Estimated Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Placebo Comparator Drug: placebo
po 30 minutes before initiation of intercourse
2: Experimental
avanafil 50 mg
Drug: avanafil
po 30 minutes before initiation of intercourse
3: Experimental
avanafil 100 mg
Drug: avanafil
po 30 minutes before initiation of intercourse
4: Experimental
avanafil 200 mg
Drug: avanafil
po 30 minutes before initiation of intercourse

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male subjects, age ≥ 18 years;
  • Minimum 6 month history of mild to severe erectile dysfunction;
  • Subject is in a monogamous, heterosexual relationship for at least 3 months;
  • Subject agrees to make at least 4 attempts at intercourse per month;
  • Subject is willing and able to provide informed consent.

Exclusion Criteria:

  • Allergy or hypersensitivity to PDE5 inhibitors;
  • History of dose-limiting AEs during therapy with a PDE5 inhibitor or hx of consistent treatment failure with other PDE5 inhibitors for therapy of ED;
  • Current or expected use of organic nitrates at any time during the study;
  • Previous or current antiandrogen therapy;
  • Use of prescription or over-the-counter drugs known to inhibit the activity of CYP3A4 at any time during the study;
  • Androgen replacement therapy that has not been stable for at least 3 month;
  • Initiation or change in dose of any alpha-blocker within 14 days prior to randomization;
  • ED as a result of spinal cord injury or radical prostatectomy;
  • Untreated hypogonadism or low serum total testosterone
  • History of or predisposition to priapism;
  • Any penile implant;
  • Elevated PSA, other evidence of prostate cancer, or previous radical prostatectomy;
  • History of any malignancy (except basal cell carcinoma or squamous cell carcinoma of the skin successfully treated by curative excision);
  • History of type 1 or type 2 diabetes;
  • Uncontrolled hypertension;
  • Hypotension;
  • Orthostatic hypotension;
  • Significant cardiovascular disease;
  • Abnormal ECG;
  • Hepatic or renal impairment;
  • Positive STD screen;
  • Clinically evident penile lesions, abrasions, or anatomical deformities;
  • Urinary tract or bladder infection;
  • Use of any treatment for erectile dysfunction other than study drug at any time during the study;
  • Participation in another investigational study within 30 days of screening or at any time during this study;
  • Previous participation in any other investigational study of avanafil;
  • History or current drug, alcohol, or substance abuse;
  • Any history of bipolar disorder or psychosis, greater than one lifetime episode of major depression, current depression of moderate or greater severity or antidepressant use that has not been stable for at least 3 months;
  • Partners who are < 18 years of age, who are nursing, who are known to be pregnant at screening, who wish to become pregnant during the study period, who have any gynecologic problems or major medical conditions that would limit participation in sexual intercourse;
  • Evidence of any other condition by history, physical examination, or laboratory studies that, in the opinion of the investigator, would contraindicate the administration of study medication, affect compliance, interfere with study evaluations, limit study participation, contraindicate sexual activity, or confound the interpretation of study results.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00790751

Contacts
Contact: Brenda Trask 650-934-5235 trask@vivus.com

  Show 40 Study Locations
Sponsors and Collaborators
VIVUS, Inc.
Quintiles
Investigators
Study Director: Chuck Bowden, MD VIVUS, Inc.
  More Information

Responsible Party: Vivus, Inc. ( Brenda Trask )
Study ID Numbers: TA-301
Study First Received: November 10, 2008
Last Updated: December 10, 2008
ClinicalTrials.gov Identifier: NCT00790751  
Health Authority: United States: Food and Drug Administration

Keywords provided by VIVUS, Inc.:
Erectile Dysfunction
E.D.
Dysfunction

Study placed in the following topic categories:
Sexual Dysfunctions, Psychological
Sexual Dysfunction, Physiological
Mental Disorders
Genital Diseases, Male
Erectile Dysfunction

Additional relevant MeSH terms:
Sexual and Gender Disorders

ClinicalTrials.gov processed this record on January 16, 2009